University of Edinburgh Medical School

Trevi Therapeutics Appoints Pharma Industry Veteran as Chief Medical Officer

Retrieved on: 
Monday, November 14, 2022
GlaxoSmithKline, Idiopathic pulmonary fibrosis, Wilson Therapeutics, IPF, U.S. Securities and Exchange Commission, Security (finance), Nalbuphine, MRCP, University of Edinburgh Medical School, Vicki Belo, Knowledge, Trevi, Royal college, Safety, United Kingdom, University, Interstitial lung disease, Prurigo nodularis, Company, Nasdaq, Therapy, Membership of the Royal Colleges of Physicians of the United Kingdom, Research, Private Securities Litigation Reform Act, Patient, COVID-19, CEO, Risk, Clinical trial, DEA, Chronic cough, Itch, Route of administration, CMO, Drug development, Disease, Cough, Pharmaceutical industry, Medicine, MD, HAVEN, Pfizer

NEW HAVEN, Conn., Nov. 14, 2022 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis (IPF) and other chronic cough indications, and for the treatment of prurigo nodularis, today announced the appointment of David Clark, MD, MRCP, as Chief Medical Officer (CMO). Dr. Clark will join Trevi's executive team and be responsible for the strategy and execution of Haduvio's clinical programs.

Key Points: 
  • Most recently, Dr. Clark served as Chief Medical Officer at Allena Pharmaceuticals, leading the Company's clinical development, regulatory and medical affairs teams.
  • Prior to that, he served as Chief Medical Officer for various companies, including Aldeyra Therapeutics, Wilson Therapeutics, and NormOxys.
  • As Chief Medical Officer, Dr. Clark has strategized and supported teams from clinical translation through Phase 3.
  • Dr. Thomas Sciascia, MD, the co-founder of Trevi Therapeutics, previously served as Trevi's Chief Medical Officer and will be transitioning to Chief Science Officer.

Neuropharmacologist and CRO Veteran Graham Birrell Joins George Clinical to Lead APAC Operations

Retrieved on: 
Monday, October 18, 2021
Central nervous system, Head, Syneos Health, Ophthalmology, Diabetes, MBA, CNS, GSK, Neuropharmacology, Lists of diseases, University, Doctor of Philosophy, ICON, APAC, University of Edinburgh Medical School, Movement disorders, Zwanzig projection operator, Multiple sclerosis, VP, Clinical trial, Dementia, Birrell, Chronic pain, IQVIA, Rheumatology, Stroke, Cros, Drug, Therapy, Drug discovery, Communication, Pfizer, CRO, Medicine, Pharmaceutical industry

Graham Birrell, PhD, MBA, a researcher and neuropharmacologist with significant clinical research experience in the EU and Asia-Pacific region has joined George Clinical, a global scientifically-backed clinical research organization, as Head, Project Operations, APAC.

Key Points: 
  • Graham Birrell, PhD, MBA, a researcher and neuropharmacologist with significant clinical research experience in the EU and Asia-Pacific region has joined George Clinical, a global scientifically-backed clinical research organization, as Head, Project Operations, APAC.
  • Birrell will also join the scientific leadership of George Clinical with a neurology focus.
  • Graham is a natural lead for our diverse APAC operations given his multifaceted background in operations, management and developing business with strategic clients, said Chief Medical Officer Maria Ali.
  • George Clinical is a leading global clinical research organization founded in Asia-Pacific driven by scientific expertise and operational excellence.